<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468714</url>
  </required_header>
  <id_info>
    <org_study_id>B1621011</org_study_id>
    <nct_id>NCT01468714</nct_id>
  </id_info>
  <brief_title>A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects</brief_title>
  <official_title>A Phase I, Open-Label, Fixed Sequence Study To Estimate The Steady-State Effect Of Ketoconazole On The Single-Dose Pharmacokinetics Of PF-04937319 In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the potential for a drug-drug interaction of PF-04937319 with
      ketoconazole, a potent inhibitor of the drug metabolizing enzyme CYP3A.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of PF-04937319</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of PF-04937319</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of PF-04937319</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(as data permits) AUCinf of PF-04937319</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(as data permits) t1/2 of PF-04937319</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of PF-04937319 M1 metabolite</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of PF-04937319 M1 metabolite</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of PF-04937319 M1 metabolite</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(as data permits) AUCinf of PF-04937319 M1 metabolite</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(as data permits) t1/2 of PF-04937319 M1 metabolite</measure>
    <time_frame>Day 1 &amp; Day 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary recovery of PF-04937319 M1 metabolite</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(as data permits) renal clearance (CLr) of PF-04937319 M1 metabolite</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Human Volunteers</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04937319 / ketoconazole</intervention_name>
    <description>Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
             Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12-lead ECG or clinical laboratory tests.

          -  Body Mass Index (BMI) of 17.5 to 29.9 kg/m2; and a total body weight &gt;=50 kg (110
             lbs).

          -  Subjects of childbearing potential must agree to use a highly effective method of
             contraception throughout the study and for at least 28-days after the last dose of
             treatment.

        Exclusion Criteria:

          -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or
             5 half-lives (whichever is longer) prior to the first dose of study medication.

          -  Pregnant or nursing females; females of childbearing potential who are unwilling or
             unable to use an acceptable method of non-hormonal contraception

          -  Consumption of grapefruit-containing products within 7 days prior to the first dose of
             study medication and while in the study protocol from at least 14 days prior to the
             first dose of study medication and for at least 28 days after the last dose of study
             medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1621011&amp;StudyName=A%20Study%20To%20Estimate%20The%20Effect%20Of%20Ketoconazole%20On%20The%20Pharmacokinetics%20Of%20Pf-04937319%20In%20Healthy%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>November 11, 2011</last_update_submitted>
  <last_update_submitted_qc>November 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>ketoconazole</keyword>
  <keyword>CYP3A</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

